We Can Answer Your Challenging Questions Involving Biomarkers and Precision Medicine.
Leverage our deep experience in the development, regulation, marketing, and utilization of clinical biomarkers, and our access to proprietary and public datasets that give us a unique ability to solve your complex problems.
Biomarker strategic plans are becoming an integral part of the drug discovery and development process. All of the top pharma are implementing or considering implementing formal, stage-gating biomarker strategic plans for all of their programs. Ensure you are keeping pace as the world of personalized medicine, driven by biomarker strategies, become the standard for drug development.
A good biomarker strategic plan allows pharmaceutical companies to:
Ensure an effective mix of biomarkers to improve a program’s likelihood of success
Establish Clinical / Mechanistic Differentiation
Recruit the right patients that are the best fit for your program
Identify the best opportunities for developing companion diagnostic partnerships
The biomarker strategic plans outline the key biomarkers and the potential impacts and applications to your programs.
Target Evaluation and Validation Report
In the earliest phases of drug discovery it is critical that the evaluation of candidate targets is comprehensive and well understood. The goal is to identify the state-of-the-art research around a candidate target and the potential surrogate biomarkers.
Amplion provides an unmatched ability to comprehensively understand a candidate target and, more importantly, surrogate biomarkers that can determine the effectivity, patient populations and, safety potential for a candidate target.
At Amplion, our services team is experienced in key target analysis and insight to ensure evidence-based go/no-go decisions in the earliest phases of a drug programs discovery and development.
We provide these solutions through detailed literature, trial, drug, and other evidence review for key biological information, especially pathway and MOA information.
Detailed literature and trial review
Biomarker interaction (e.g. up regulated, down regulated)
Gene expression study findings
Detailed data from relevant studies
Whether you’re looking to deepen your thought leadership role, or understand the opportunity a therapeutic program represents, Amplion’s service team can provide the insight to increase your market success.
As new technologies, approaches, and innovations emerge, Amplion is well positioned to provide the actionable insights needed to establish your market success.
We have provided deep market analysis and thought leadership in the following areas:
Liquid biopsy market trends, state of development and impact on precision medicine
Which drug companies are market leaders in the use of biomarkers and the development of personalized therapeutics?
How are biomarker-based tests regulated and reimbursed, and how do these factors influence go-to-market strategies for new test products?
What are the best opportunities for developing companion diagnostic partnerships?